Jan de Backer – CEO, Fluidda
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Address: Groeningenlei 132
2550 Kontich
Groeningenlei 132, 2550 Kontich,Belgium
Tel: +32 3 450 87 20
FluidDA acts as a CRO to support the implementation of the FluidDA imaging biomarkers into clinical trials and clinical practice. To offer a high quality service, FluidDA employs experts in all required fields from medical doctors to biomedical scientists and engineers. A complete package is offered to manage a study from design to (scientific) reporting.
FluidDA has experience in pulmonology, respiratory drug delivery, sleep medicine, maxillofacial surgery and cardiovascular. The company collects stores, manages and analyzes data coming from a variety of imaging modalities such as CT, MRI, Cone Beam CT, SPECT and ultrasound. From clinical studies, FluidDA has gained extensive experience in scanning protocols to achieve proper image quality. FluidDA can write or assist in writing protocols for clinical imaging studies according to GCP guidelines as well as analyzing and writing of study results in international peer reviewed journals.
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Dr De Backer looking into your background, we see that you have a background in aerospace engineering and applied biomedical computational fluid dynamics that is riddled with awards for your…
Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some…
Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Werner De Prins oversees Bayer’s operations in Benelux, a significant region for the global group with over 2000 employees, a turnover of around EUR 1.2 billion and 10 different sites…
Stefan Joris of the Belgian Cystic Fibrosis Association (BCFA) highlights the progress that has been made on cystic fibrosis screening of newborns and reimbursement of innovative modulator therapies in Belgium…
Dr Frank Nobels, one of Belgium’s leading endocrinologists and diabetologists, introduces the Belgian Diabetes Forum – a multi-stakeholder initiative which aims to create efficient policy engagement in diabetes and make…
With two in-house Clinical Research Units (PCRUs), Pfizer uniquely keeps its phase I research within the company. As Medical/Scientific advisor at the Brussels PCRU and with a history of more…
After almost 20 years with AbbVie, Renaud Decroix still feels as engaged and motivated as ever by the goal of having a remarkable impact on patients’ lives. Decroix highlights some…
Medaxes – the Belgian industry association for companies producing generic and biosimilar medicines, as well as other off-patent medicines and self-care products – welcomed a new CEO in 2022, Jasmien…
Théa veteran and GM of the French ophthalmology midcap’s BeLux affiliate, Ivan Perrichon, reveals the company’s plans to pursue its growth trajectory, launch ten new products in Belgium and reach…
Belgium is a hugely significant country for GSK – which employs 9,000 people in the country – as host to three of the firm’s major vaccine sites, the global headquarters…
Paul Newton of Vertex Pharmaceuticals – one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry – outlines the company’s footprint…
See our Cookie Privacy Policy Here
